At Asha Therapeutics we are developing novel, first-in-class compounds targeting the point of greatest therapeutic impact for diseases with high unmet medical need. We have active programs in neuroscience for therapeutic intervention in neurodegenerative diseases including Parkinson's Disease (PD), Alzheimer's Disease (AD), and Amyotrophic Lateral Sclerosis (ALS), post-viral illnesses such as Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long Haul COVID, as well as Ischemic Stroke and Neuro-oncology.